| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
|
| | 7H-Pyrrolo[2,3-d]pyridazin-7-one, 4-amino-3-[4-(2,6-difluorophenoxy)phenyl]-1,6-dihydro-1-[(3R)-1-(1-oxo-2-butyn-1-yl)-3-pyrrolidinyl]- Basic information |
| Product Name: | 7H-Pyrrolo[2,3-d]pyridazin-7-one, 4-amino-3-[4-(2,6-difluorophenoxy)phenyl]-1,6-dihydro-1-[(3R)-1-(1-oxo-2-butyn-1-yl)-3-pyrrolidinyl]- | | Synonyms: | 7H-Pyrrolo[2,3-d]pyridazin-7-one, 4-amino-3-[4-(2,6-difluorophenoxy)phenyl]-1,6-dihydro-1-[(3R)-1-(1-oxo-2-butyn-1-yl)-3-pyrrolidinyl]-;4-Amino-3-[4-(2,6-difluoro-phenoxy)-phenyl]-1-[1-(1-oxo-but-2-ynyl)-pyrrolidin-3-yl]-1,6-dihydro-pyrrolo[2,3-d]pyridazin-7-one;TG-1701;(R)-4-amino-1-(1-(but-2-ynoyl)pyrrolidin-3-yl)-3-(4-(2,6-difluorophenoxy)phenyl)-1,6-dihydro-7H-pyrrolo[2,3-d]pyridazin-7-one;4-Amino-1-[(3R)-1-(but-2-ynoyl)pyrrolidin-3-yl]-3-[4-(2,6-difluorophenoxy)phenyl]-1H,6H,7H-pyrrolo[2,3-d]pyridazin-7-one;Edralbrutinib;4-Amino-3-[4-(2,6-difluorophenoxy)phenyl]-1,6-dihydro-1-[(3R)-1-(1-oxo-2-butyn-1-yl)-3-pyrrolidinyl]-7H-pyrrolo[2,3-d]pyridazin-7-one (ACI) | | CAS: | 1858206-58-2 | | MF: | C26H21F2N5O3 | | MW: | 489.47 | | EINECS: | | | Product Categories: | | | Mol File: | 1858206-58-2.mol | ![7H-Pyrrolo[2,3-d]pyridazin-7-one, 4-amino-3-[4-(2,6-difluorophenoxy)phenyl]-1,6-dihydro-1-[(3R)-1-(1-oxo-2-butyn-1-yl)-3-pyrrolidinyl]- Structure](CAS/20210305/GIF/1858206-58-2.gif) |
| | 7H-Pyrrolo[2,3-d]pyridazin-7-one, 4-amino-3-[4-(2,6-difluorophenoxy)phenyl]-1,6-dihydro-1-[(3R)-1-(1-oxo-2-butyn-1-yl)-3-pyrrolidinyl]- Chemical Properties |
| density | 1.43±0.1 g/cm3(Predicted) | | pka | 8.89±0.40(Predicted) | | form | Solid | | color | White to off-white |
| | 7H-Pyrrolo[2,3-d]pyridazin-7-one, 4-amino-3-[4-(2,6-difluorophenoxy)phenyl]-1,6-dihydro-1-[(3R)-1-(1-oxo-2-butyn-1-yl)-3-pyrrolidinyl]- Usage And Synthesis |
| Uses | Edralbrutinib (TG-1701) is a potent BTK inhibitor[1]. | | References | [1] JIANGSU HENGRUI MEDICINE CO, et al. Pharmaceutically acceptable salt and crystal form of pyrrolo[2,3-d]pyridazin-7-one derivative and preparation method of medicinal salt and crystal form. WO2018210296A1. |
| | 7H-Pyrrolo[2,3-d]pyridazin-7-one, 4-amino-3-[4-(2,6-difluorophenoxy)phenyl]-1,6-dihydro-1-[(3R)-1-(1-oxo-2-butyn-1-yl)-3-pyrrolidinyl]- Preparation Products And Raw materials |
|